Recent technology advances especially transcriptome sequencing and bioinformatics strategy for processing cancer profiling data, make the discovery of more fusion genes in cancers, including a recurrent chimeric transcript DNAJB1-PRKACA in FL-HCC [9] and SLC45A3-ELK4 in prostate cancers [23], etc. These known fusion genes provide key insights into tumor biology and have significant clinical impact by serving as potential diagnostic markers or therapeutic targets. The gene discussed is SLC45A3; the disease is prostate carcinoma.